Zydus Lifesciences Ltd

In a regulatory filing, the company confirmed that the USFDA conducted a follow-up inspection focused on good manufacturing practices (GMP) from 9 June to 18 June 2025. Upon conclusion of the inspection, the US health regulator issued two observations. Zydus clarified that the observations are not related to data integrity. The company further stated that it will work closely with the USFDA to address the issues raised and will submit its response within an expeditious manner. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. The counter shed 0.40% to Rs 954 on the BSE. Powered by Capital Market - Live

The appointment was approved by the nomination and remuneration committee (NRC). Swati Dalal is part of the senior management team at Zydus Lifesciences and brings extensive leadership experience to her new role as Managing Director of Zydus Healthcare. Swati Dalal is a seasoned commercial leader with over 30 years of rich and diverse experience in the healthcare and pharmaceutical industry. She began her career with Wockhardt Nutrition before moving to the erstwhile Boots, where she continued through successive mergers with Knoll, Solvay, and Abbott, progressively taking on leadership roles across the organisation. During her tenure at Abbott, she held various senior positions across both commercial and support functions. These included commercial director ' sales & marketing, as well as leadership of new product introductions (NPI), business development, and commercial excellence. She later served as managing director of Abbott Nutrition and Abbott Primary Care, and most recently, as managing director of Abbott India. Swati has also been a strong proponent of employee development and inclusion. She has led and contributed to initiatives such as women leaders of Abbott, the early career network, and has actively championed Abbott's diversity, equity, and inclusion (DEI) agenda in India. Swati holds a pharmacy degree from P.K.M. Kundnani College of Pharmacy, Mumbai and a post-graduate degree in Management Studies from Jamnalal Bajaj Institute of Management Studies in Mumbai. Swati Dalal is not related to any of the directors of Zydus Lifesciences or its wholly owned subsidiary, Zydus Healthcare. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. Shares of Zydus Lifesciences shed 0.51% to Rs 970 on the BSE. Powered by Capital Market - Live

Zydus Lifesciences has approved the appointment of s. Swati Dalal as the Additional Director and the Managing Director of ZHL with effect from June 16, 2025 for a period of 5 (five) years.Powered by Capital Market - Live

Zydus Lifesciences has received the Establishment Inspection Report (EIR) report from the US FDA for the inspection conducted at its API manufacturing facility located at Ankleshwar. This facility underwent an inspection from 10th to 14th March 2025, and the inspection has been classified as No Action Indicated (NAI). The USFDA has concluded that this inspection is 'closed'. Powered by Capital Market - Live

The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the review, the inspection has been classified as no action indicated (NAI). The USFDA has concluded that the inspection is now closed. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. Shares of Zydus Lifesciences shed 0.36% to Rs 975.20 on the BSE. Powered by Capital Market - Live

The facility underwent an inspection from April 21 to April 25, 2025. The inspection has been classified as Voluntary Action Indicated (VAI), with the FDA confirming the inspection as closed. The company's consolidated net profit shed 0.96% to Rs 1,170.9 crore on 17.21% rise in revenue from operations to Rs 6290.2 crore in Q4 FY25 over Q4 FY24. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Shares of Zydus Lifesciences rose 0.71% to Rs 980 on the BSE. Powered by Capital Market - Live

  Zydus Lifesciences has received the EIR report from the USFDA for the inspection conducted at its API manufacturing facility located at Dabhasa near Vadodara. This facility underwent an inspection from 21st to 25th April 2025 and has been classified as Voluntary Action Indicated (VAI). FDA confirmed the inspection as 'closed'.  Powered by Capital Market - Live

Zydus Lifesciences Ltd is up for a fifth straight session today. The stock is quoting at Rs 976, up 0.24% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.13% on the day, quoting at 25136.5. The Sensex is at 82493.19, up 0.06%. Zydus Lifesciences Ltd has gained around 10.3% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has gained around 3.79% in last one month and is currently quoting at 21826.8, up 0.35% on the day. The volume in the stock stood at 4.89 lakh shares today, compared to the daily average of 11.15 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 983.3, up 0.79% on the day. Zydus Lifesciences Ltd is down 10.03% in last one year as compared to a 8.04% jump in NIFTY and a 11.24% jump in the Nifty Pharma index.The PE of the stock is 16.96 based on TTM earnings ending March 25.Powered by Capital Market - Live

Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets will be produced at the Group's manufacturing facility at SEZ II, Ahmedabad. According to IQVIA MAT 2025, Rifaximin tablets had annual sales of USD $2,672.9 million in the United States. The group now has 427 approvals and has filed 492 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04. The company's consolidated net profit shed 0.96% to Rs 1,170.9 crore on 17.21% rise in revenue from operations to Rs 6290.2 crore in Q4 FY25 over Q4 FY24. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Shares of Zydus Lifesciences shed 0.53% to Rs 924.95 on the BSE. Powered by Capital Market - Live

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Rifaximin Tablets, 550 mg (USRLD: Xifaxan' Tablets, 550 mg). Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Rifaximin tablets will be produced at the Group's manufacturing site at SEZ II, Ahmedabad. Rifaximin tablets had annual sales of USD $2672.9 mn in the United States (IQVIA MAT March 2025).Powered by Capital Market - Live